After my review of the Pfizer/BioNTech SARS-CoV-2 virus vaccine, I was regularly asked if I would do the same for the Moderna vaccine. I will do that in this blog. Regarding a discussion of the study into the efficacy and safety of the.
In January of 2021, the U.S. Equal Employment Opportunity Commission (EEOC) – a government agency that advances opportunity in the workplace by enforcing federal laws prohibiting employment discrimination – announced that President Joe Biden had appointed Commissioner Charlotte A. Burrows Chair of the EEOC and Commissioner Jocelyn Samuels Vice Chair of the EEOC as part of the Commission of the EEOC.
Burrows had served as an EEOC Commissioner since 2015, having been initially nominated by President Barack Obama. In 2019, she was re-nominated and unanimously confirmed for a second term ending in 2023. “I am deeply honored to be chosen by President Biden to lead the Equal Employment Opportunity Commission,” Chair Burrows stated in a press release about the appointments from the EEOC.
A biotechnology company working on a vaccine to prevent HIV, whose work is licensed by UMass Medical School in Worcester, has won U.S. Food and Drug Administration approval to advance its clinical work.
The firm, Worcester HIV Vaccine, was approved for the FDA s investigational new drug process for a vaccine that s aimed at preventing the virus that causes AIDS. An early-stage clinical trial is expected to start this month, with a second-phase trial to follow, the medical school said Friday.
Image
Dr. Shan Lu
The potential vaccine is based on discoveries by Dr. Shan Lu, a professor of medicine at UMass Medical School and licensed by the Worcester school. Worcester HIV Vaccine was founded more than two years ago, and the investigational drug approval by the FDA is a major achievement in its development, Yegor Veronin, the firm s COO, said in a statement.
Full Year and Fourth Quarter Highlights:
CVS Health logo (PRNewsFoto/CVS Health)
Full year total revenues increased to $268.7 billion, up 4.6% compared to prior year
Full year and fourth quarter GAAP diluted earnings per share from continuing operations of $5.47 and $0.75
Full year and fourth quarter Adjusted EPS of $7.50 and $1.30
Generated full year cash flow from operations of $15.9 billion
Results reflect COVID-19 impacts and related investments
2021 Full Year Guidance:
Adjusted EPS in the range of $7.39 to $7.55
Cash flow from operations in the range of $12.0 billion to $12.5 billion
CVS Health Corporation (NYSE: CVS) today announced operating results for the three months and year ended December 31, 2020.